ICLR · Icon PLC
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICLR
this stock
Icon PLC
|
$13.31B | -5.3% | +19.8% | 265.4 | 2.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$231.21B | +5.9% | +14.5% | 33.6 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -5.7% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.86B | +41.9% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -16.9% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICLR | +3.2% | +3.1% | +62.5% | +5.5% | -5.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +3.6% | +0.2% | +51.0% | +2.5% | -18.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.